Apyx Medical (APYX) 10-Q 9 Nov 23 2023 Q3 Quarterly report Financial data

Cover

Cover - shares	9 Months Ended
	Sep. 30, 2023	Nov. 08, 2023
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Sep. 30, 2023
Document Transition Report	false
Entity File Number	001-31885
Entity Registrant Name	APYX MEDICAL CORPORATION
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	11-2644611
Entity Address, Address Line One	5115 Ulmerton Road,
Entity Address, City or Town	Clearwater
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33760
City Area Code	727
Local Phone Number	384-2323
Title of 12(b) Security	Common Stock
Trading Symbol	APYX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		34,643,855
Entity Central Index Key	0000719135
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2023

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 22,134	$ 10,192
Trade accounts receivable, net of allowance of $652 and $668	12,648	10,602
Income tax receivables	0	7,545
Other receivables	596	99
Inventories, net of provision for obsolescence of $611 and $457	11,285	11,797
Prepaid expenses and other current assets	3,487	2,737
Total current assets	50,150	42,972
Property and equipment, net	2,093	6,761
Operating lease right-of-use assets	5,274	710
Finance lease right-of-use assets	74	115
Other assets	1,855	1,217
Total assets	59,446	51,775
Current liabilities:
Accounts payable	2,050	2,669
Accrued expenses and other current liabilities	7,914	8,928
Current portion of operating lease liabilities	310	216
Current portion of finance lease liabilities	20	37
Total current liabilities	10,294	11,850
Term loan, net	9,009	0
Long-term operating lease liabilities	4,992	470
Long-term finance lease liabilities	58	73
Long-term contract liabilities	1,326	1,408
Other liabilities	181	181
Total liabilities	25,860	13,982
EQUITY
Preferred stock, $0.001 par value; 10,000,000 shares authorized; 0 issued and outstanding as of September 30, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value; 75,000,000 shares authorized; 34,643,855 issued and outstanding as of September 30, 2023, and 34,597,822 issued and outstanding as of December 31, 2022	35	35
Additional paid-in capital	78,154	73,282
Accumulated deficit	(44,841)	(35,735)
Total stockholders’ equity	33,348	37,582
Non-controlling interest	238	211
Total equity	33,586	37,793
Total liabilities and equity	$ 59,446	$ 51,775

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Allowance for doubtful accounts receivable	$ 652	$ 668
Inventories, provision for obsolescence	$ 611	$ 457
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	10,000,000	10,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	75,000,000	75,000,000
Common stock, shares issued (in shares)	34,643,855	34,597,822
Common stock, shares outstanding (in shares)	34,643,855	34,597,822

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Statement [Abstract]
Sales	$ 11,976	$ 9,114	$ 37,687	$ 31,899
Cost of sales	3,998	3,357	12,857	11,009
Gross profit	7,978	5,757	24,830	20,890
Other costs and expenses:
Research and development	1,276	1,061	3,596	3,289
Professional services	1,831	1,936	5,165	6,611
Salaries and related costs	4,667	3,871	14,770	13,944
Selling, general and administrative	4,841	4,671	15,474	14,675
Total other costs and expenses	12,615	11,539	39,005	38,519
Gain on sale-leaseback	0	0	2,692	0
Loss from operations	(4,637)	(5,782)	(11,483)	(17,629)
Interest income	248	73	478	93
Interest expense	(585)	(1)	(1,362)	(12)
Other (expense) income, net	(19)	(35)	622	551
Total other (expense) income, net	(356)	37	(262)	632
Loss before income taxes	(4,993)	(5,745)	(11,745)	(16,997)
Income tax (benefit) expense	(318)	50	(2,519)	216
Net loss	(4,675)	(5,795)	(9,226)	(17,213)
Net loss attributable to non-controlling interest	(46)	(31)	(120)	(78)
Net loss attributable to stockholders	$ (4,629)	$ (5,764)	$ (9,106)	$ (17,135)
Loss per share:
Basic (in dollars per share)	$ (0.13)	$ (0.17)	$ (0.26)	$ (0.50)
Diluted (in dollars per share)	$ (0.13)	$ (0.17)	$ (0.26)	$ (0.50)

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit	Non-controlling Interest
Beginning balance (in shares) at Dec. 31, 2021		34,410
Beginning balance at Dec. 31, 2021	$ 54,009	$ 34	$ 66,221	$ (12,551)	$ 305
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		106
Shares issued on stock options exercises for cash	365	$ 1	364
Stock based compensation	5,056		5,056
Shares issued on net settlement of stock options (in shares)		72
Net loss	(17,213)			(17,135)	(78)
Ending balance (in shares) at Sep. 30, 2022		34,588
Ending balance at Sep. 30, 2022	42,217	$ 35	71,641	(29,686)	227
Beginning balance (in shares) at Jun. 30, 2022		34,493
Beginning balance at Jun. 30, 2022	46,163	$ 34	69,793	(23,922)	258
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Shares issued on stock options exercises for cash (in shares)		62
Shares issued on stock options exercises for cash	157	$ 1	156
Stock based compensation	1,692		1,692
Shares issued on net settlement of stock options (in shares)		33
Net loss	(5,795)			(5,764)	(31)
Ending balance (in shares) at Sep. 30, 2022		34,588
Ending balance at Sep. 30, 2022	42,217	$ 35	71,641	(29,686)	227
Beginning balance (in shares) at Dec. 31, 2022		34,598
Beginning balance at Dec. 31, 2022	37,793	$ 35	73,282	(35,735)	211
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	147				147
Shares issued on stock options exercises for cash (in shares)		35
Shares issued on stock options exercises for cash	86		86
Stock based compensation	4,200		4,200
Shares issued on net settlement of stock options (in shares)		11
Proceeds received from issuance of warrants	586		586
Net loss	(9,226)			(9,106)	(120)
Ending balance (in shares) at Sep. 30, 2023		34,644
Ending balance at Sep. 30, 2023	33,586	$ 35	78,154	(44,841)	238
Beginning balance (in shares) at Jun. 30, 2023		34,629
Beginning balance at Jun. 30, 2023	36,733	$ 35	76,773	(40,212)	137
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Contributions from non-controlling interest	147				147
Shares issued on stock options exercises for cash (in shares)		10
Shares issued on stock options exercises for cash	30		30
Stock based compensation	1,351		1,351
Shares issued on net settlement of stock options (in shares)		5
Net loss	(4,675)			(4,629)	(46)
Ending balance (in shares) at Sep. 30, 2023		34,644
Ending balance at Sep. 30, 2023	$ 33,586	$ 35	$ 78,154	$ (44,841)	$ 238

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022
Cash flows from operating activities
Net loss	$ (9,226)	$ (17,213)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	540	688
Provision for inventory obsolescence	229	158
(Gain) loss on disposal of property and equipment	(2,656)	76
Stock based compensation	4,200	5,056
Provision for allowance for doubtful accounts	176	283
Non-cash interest expense	354	0
Non-cash lease expense	56	0
Changes in operating assets and liabilities:
Trade receivables	(2,192)	3,273
Prepaid expenses and other assets	(698)	(521)
Income tax receivables	7,545	97
Inventories	401	(5,672)
Accounts payable	(613)	(439)
Accrued and other liabilities	(1,153)	(1,536)
Net cash used in operating activities	(3,037)	(15,750)
Cash flows from investing activities
Purchases of property and equipment	(440)	(868)
Proceeds from sale of property and equipment	7,267	0
Net cash provided by (used in) investing activities	6,827	(868)
Cash flows from financing activities
Proceeds from stock option exercises	86	365
Proceeds from term loan	9,289	0
Payment of debt issuance costs	(1,754)	0
Proceeds from issuance of warrants	586	0
Repayment of finance lease liabilities	(32)	(138)
Contributions from non-controlling interest	147	0
Net cash provided by financing activities	8,322	227
Effect of exchange rates on cash	(170)	354
Net change in cash and cash equivalents	11,942	(16,037)
Cash and cash equivalents, beginning of period	10,192	30,870
Cash and cash equivalents, end of period	22,134	14,833
Cash paid for:
Interest	834	12
Income taxes	261	128
Non cash activities:
Right-of-use assets capitalized and operating lease liabilities recognized upon execution of lease	4,917	0
Right-of-use assets capitalized and operating lease liabilities recognized upon lease modification	0	769
Right-of-use assets capitalized and finance lease liabilities recognized upon execution of lease	0	103
Right-of-use assets and finance lease liabilities derecognized upon execution of lease modification	$ 0	$ 28

BASIS OF PRESENTATION

BASIS OF PRESENTATION	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Apyx Medical Corporation (“Company”, “Apyx”, “it” and similar terms) was incorporated in 1982, under the laws of the State of Delaware and has its principal executive office at 5115 Ulmerton Road, Clearwater, FL 33760. The Company is an advanced energy technology company with a passion for elevating people’s lives through innovative products, including its Helium Plasma Technology products marketed and sold as Renuvion® in the cosmetic surgery market and J-Plasma® in the hospital surgical market. Renuvion® and J-Plasma® offer surgeons a unique ability to provide controlled heat to tissue to achieve their desired results. The Company also leverages its deep expertise and decades of experience in unique waveforms through OEM agreements with other medical device manufacturers. As part of its plan to accelerate and fully fund the development of its advanced energy business, with a focus in the cosmetic surgery market, the Company sold its Core business in 2018 for gross proceeds of $97 million. These proceeds were used to launch broad marketing and sales initiatives which resulted in rapid sales growth through December 31, 2021 and into the first quarter of 2022. This planned growth in the business was accompanied by scaled operations, including procurement of components, expanded manufacturing capacity to turn those materials into saleable inventory, additional discretionary expenditures, including increased global participation at trade shows, additional employee trainings, user meetings, increased travel and entertainment expenses, more expansive research and development projects, and additional headcount to support those activities. Additionally, the Company had, and still has, some significant non-recurring discretionary expenditures associated with completing its multi-year marketing initiatives related to its dermal resurfacing and skin laxity clearances. On March 14, 2022, the U.S. Food and Drug Administration (“FDA”) posted a Medical Device Safety Communication (“Safety Communication”). The FDA warned against the use of Renuvion/J-Plasma for procedures intended to improve the appearance of the skin through dermal resurfacing (a procedure on the skin to treat wrinkles) or skin contraction (a procedure under the skin that can be performed either alone or in combination with liposuction to achieve skin effects, such as “tightening”). At that time, the Renuvion/J-Plasma device system was FDA cleared for general use of cutting, coagulation, and ablation of soft tissue during open and laparoscopic surgical procedures, but had not yet been determined to be safe or effective for any aesthetic skin procedures (procedures intended to improve the appearance of the skin). Following the Safety Communication, the Company experienced slowed demand for the adoption of its Helium Plasma Technology. On May 26, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® Dermal Handpiece for certain dermal resurfacing procedures, specifically, for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick Skin Types I, II or III. On June 2, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the new 510(k) clearance for the Renuvion® device system for certain dermal resurfacing procedures. On July 18, 2022, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for use in subcutaneous dermatological and aesthetic procedures to improve the appearance of lax (loose) skin in the neck and submental (under the chin) region. On July 21, 2022, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpieces for use under the skin in certain procedures intended to improve the appearance of loose skin. On February 27, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for the delivery of radiofrequency energy and/or helium plasma where coagulation/contraction of soft tissue is needed. Soft tissue includes subcutaneous tissue. On April 28, 2023, the Company announced that it received 510(k) clearance from the FDA for the use of the Renuvion® APR Handpiece for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. On May 10, 2023, the FDA updated the Safety Communication to inform consumers and healthcare providers about the clearance for the Renuvion® APR handpiece for use under the skin in certain procedures intended to improve the appearance of the skin, including for coagulation of subcutaneous soft tissues following liposuction for aesthetic body contouring. The May 10, 2023 FDA update to the Safety Communication addresses the issues set forth in the original Safety Communication from March 14, 2022. Management believes that receiving these additional clearances and the corresponding updates to the Safety Communication since March 14, 2022 should assist in mitigating the financial effects of the Safety Communication in future periods. The accompanying unaudited condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The going concern basis of presentation assumes that the Company will continue in operation one year after the date these financial statements are issued and will be able to realize its assets and discharge its liabilities and commitments in the normal course of business. Pursuant to the requirements of the Financial Accounting Standards Board’s Accounting Standards Codification (“ASC”) Topic 205-40, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern , management must evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern for one year from the date these unaudited condensed consolidated financial statements are issued. This evaluation does not take into consideration the potential mitigating effect of management’s plans that have not been fully implemented or are not within control of the Company as of the date the unaudited condensed consolidated financial statements are issued. When substantial doubt exists under this methodology, management evaluates whether the mitigating effect of its plans sufficiently alleviates substantial doubt about the Company’s ability to continue as a going concern. The mitigating effect of management’s plans, however, is only considered if both (1) it is probable that the plans will be effectively implemented within one year after the date that the financial statements are issued, and (2) it is probable that the plans, when implemented, will mitigate the relevant conditions or events that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued. While sales were continuing to grow into the first quarter of 2022 prior to the FDA Safety Communication, over the last few years, exclusive of the Company’s sale of the Core business segment to Symmetry Surgical during 2018, the Company has incurred recurring net losses and cash outflows from operations and the Company anticipates that losses will continue in the near term. During the year ended December 31, 2022, the Company incurred an operating loss of $23.6 million and used $20.3 million of cash in operations. During the nine months ended September 30, 2023, the Company incurred an operating loss of $11.5 million and used $11.1 million of cash in operations exclusive of the receipt of the Company's tax refund, including interest, of approximately $8.1 million. As of September 30, 2023, the Company had cash and cash equivalents of $22.1 million, of which the Company must maintain $10.0 million under its Credit Agreement. These conditions raise substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of these unaudited condensed consolidated financial statements. In an effort to alleviate these conditions, the Company pursued various funding solutions in order to improve liquidity. On November 22, 2022, the Company filed a shelf registration statement providing it the ability to register securities in the aggregate amount up to $100 million. The shelf registration included an embedded ATM facility for up to $40 million. To date, the Company has not utilized this facility. On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”) with MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time. The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to certain percentages of the Company’s eligible accounts receivable and inventory, as determined in accordance with the terms of the MidCap Credit Agreement. On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto. The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million. For a more in depth description of the terms of the MidCap Credit Agreement and the Perceptive Credit Agreement, see Note 7. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company’s real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser. For a more in depth description of the terms of the Purchase Agreement, see Notes 4 and 5. During January 2023, the Company was notified that the IRS examination process of our 2018, 2019 and 2020 tax returns was complete and that the Company’s tax refunds were approved for approximately $0.2 million more than the amount recorded in the Company’s Consolidated Balance Sheet at December 31, 2022. On August 10, 2023, the Company received $8.1 million from the IRS, which included approximately $0.4 million of interest on the $7.7 million income tax refunds. The Company also re-assessed its operating expenditures and cost structure and made adjustments in light of expected levels of revenue. This included reducing some operating expenditures, including a reduction-in-force on January 9, 2023, that reduced the Company’s U.S. headcount by 14%. Management believes that the actions already taken, including replacing the MidCap Credit Agreement with the Perceptive Credit Agreement, alleviate the conditions that raised substantial doubt about the Company’s ability to continue as a going concern for a period of at least one year from the date of issuance of its unaudited condensed consolidated financial statements.

RECENT ACCOUNTING PRONOUNCEMENT

RECENT ACCOUNTING PRONOUNCEMENTS	9 Months Ended
	Sep. 30, 2023
Accounting Standards Update and Change in Accounting Principle [Abstract]
RECENT ACCOUNTING PRONOUNCEMENTS	RECENT ACCOUNTING PRONOUNCEMENTS In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.

INVENTORIES

INVENTORIES	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours. Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 4,578 $ 4,979 Work in process 2,522 2,160 Finished goods 4,796 5,115 Gross inventories 11,896 12,254 Less: provision for obsolescence (611) (457) Inventories, net $ 11,285 $ 11,797

PROPERTY AND EQUIPMENT

PROPERTY AND EQUIPMENT	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	PROPERTY AND EQUIPMENT (In thousands) September 30, 2023 December 31, Land $ — $ 1,600 Building and improvements — 4,426 Machinery and equipment 2,635 2,613 Furniture and fixtures 216 211 Computer equipment and software 1,079 1,420 Leasehold improvements 178 178 Molds 1,017 847 Total property, plant and equipment 5,125 11,295 Less: accumulated depreciation and amortization (3,489) (5,041) Property and equipment in service 1,636 6,254 Construction in progress 457 507 Property and equipment, net $ 2,093 $ 6,761 In an effort to improve liquidity and the balance sheet condition of the Company, management explored options to leverage the Company’s unencumbered real property. On February 27, 2023, the Company’s Board of Directors approved a plan to sell and leaseback the Company's real property located in Clearwater, FL. On March 14, 2023, the Company entered into a Purchase and Sale Agreement (the “Purchase Agreement”) with VK Acquisitions VI, LLC (the “Purchaser”), for the sale of the Company’s facility located at 5115 Ulmerton Road, Clearwater, Florida, as more fully described in the Purchase Agreement (collectively, the “Property”) for a purchase price of $7,650,000. On May 8, 2023, the Company closed on the Purchase Agreement and concurrently executed a 10-year agreement to leaseback the underlying Property from the Purchaser (see Note 5). The Company received net cash proceeds of approximately $6,600,000, after withholding the security deposit of approximately $0.6 million, equal to one year's rent, taxes, first months rent, expenses, and fees. The $2,700,000 gain on this transaction is presented in gain on sale-leaseback in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2023.

LEASES

LEASES	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
LEASES	LEASES Operating Leases The Company leases its facility in Sofia, Bulgaria and computers under non-cancelable operating lease agreements. These operating leases have terms expiring through December 2027. In connection with the terms of the Purchase Agreement (see Note 4), during May 2023, the Company entered into a Single Tenant Industrial Building Lease (the “Lease”), pursuant to which the Property was leased back to the Company. The Lease has an initial term of ten (10) years commencing from the closing (the “Initial Term”), and a renewal term of five (5) years, exercisable at the Company’s option. The annual fixed rent is $619,500 for the first year of the Initial Term, and is subject to a 4% escalation every year thereafter through the Initial Term. Rent will be reset to the current market rate should the Company exercise the renewal option. The Lease provides for a 3% management fee on rent payments throughout the Initial Term and optional renewal term. The Lease is a triple net lease, pursuant to which all costs, expenses, and obligations relating to the Property, including, repair and maintenance charges, utility charges, real estate taxes or other taxes that may be imposed that relate to the Property, shall be paid by the Company. In addition, the Lease contains other customary terms and provisions generally contained within leases of this type. Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows: September 30, 2023 December 31, Weighted average remaining lease term (in years) 9.2 4.4 Weighted average discount rate 8.42% 2.54% Maturities of operating lease liabilities as of September 30, 2023 are as follows: (In thousands) 2023 $ 190 2024 773 2025 799 2026 826 2027 855 Thereafter 4,516 Total lease payments 7,959 Less imputed interest (2,657) Present value of lease liabilities 5,302 Less current portion of lease liabilities (310) Long-term portion of lease liabilities $ 4,992

ACCRUED EXPENSES AND OTHER CURR

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES	ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, December 31, Accrued payroll $ 879 $ 563 Accrued bonuses 1,188 — Accrued commissions 1,183 847 Accrued product warranties 386 391 Accrued product liability claim insurance deductibles 2,060 1,825 Accrued professional fees and legal related contingent liabilities 607 901 Joint and several payroll liability — 345 Short-term contract liabilities 712 853 Uncertain tax positions — 2,079 Sales tax payable 245 245 Other accrued expenses and current liabilities 654 879 Total accrued expenses and other current liabilities $ 7,914 $ 8,928 During April 2023, the Company was relieved of the remainder of its joint and several payroll liability due to the lapse of the statute of limitations. This adjustment is included in other (expense) income, net for the nine months ended September 30, 2023.

DEBT

DEBT	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
DEBT	DEBT Included in interest expense for the three and nine months ended September 30, 2023 are $36,000 and $87,000, respectively, of amortization of the debt issuance costs and $81,000 and $198,000, respectively, of amortization of the debt discounts including accretion of the exit fee on the term loan. Included in interest expense for the three and nine months ended September 30, 2023 are $25,000 and $62,000, respectively, of amortization of the debt issuance costs and $3,000 and $7,000, respectively, of amortization of the debt discount on the revolving facility. The Company’s term loan, net consists of the following at September 30, 2023: (In thousands) Term loan $ 10,000 Unamortized debt issuance costs (414) Unamortized debt discount, including accretion of exit fee (577) Term loan, net $ 9,009 The term loan, net was paid in full on November 8, 2023 in connection with the execution of the Perceptive Credit Agreement. The Company is still determining the appropriate accounting treatment for the MidCap Credit Agreement and Perceptive Credit Agreement. While the Perceptive Credit Agreement contains a subjective acceleration clause, management has determined that there is remote probability that Perceptive would accelerate of the obligations under the subjective acceleration clause. Accordingly, term loan, net has been presented as a long term liability in the accompanying condensed consolidated balance sheet as of September 30, 2023. The Company expects to record a loss on extinguishment of the MidCap Credit Agreement of approximately $2.5 million in connection with the write-off of unamortized debt issuance costs, debt discounts and unamortized debt premiums. MIDCAP CREDIT AGREEMENT On February 17, 2023, the Company entered into a Credit, Security and Guaranty Agreement (the “MidCap Credit Agreement”), by and among the Company (as borrower) and Apyx China Holding Corp., the Company’s wholly-owned subsidiary (as guarantor), and MidCap Funding IV Trust (as agent), and MidCap Financial Trust (as term loan servicer), and the lenders party thereto from time to time (collectively “MidCap”). The MidCap Credit Agreement provided for an up to $35 million facility, consisting of senior secured term loans and a secured revolving facility. The MidCap Credit Agreement provided for senior secured term loans of up to $25 million, comprised of (i) an initial tranche of $10 million, (ii) a second tranche of $5 million, and (iii) a third tranche of $10 million. The secured revolving facility provided for loans in an aggregate principal amount of up to $10 million, subject to a borrowing base equal to percentages of eligible accounts receivable and inventory determined in accordance with the MidCap Credit Agreement. The MidCap Credit Agreement was to mature on February 1, 2028. The outstanding borrowings under the MidCap Credit Agreement were repaid in full using proceeds from the execution of the Perceptive Credit Agreement. Term Loans The initial tranche of $10 million was fully funded on February 17, 2023 less transaction costs. Subject to certain terms and conditions of the MidCap Credit Agreement, the second tranche would be available between June 30, 2023 and December 31, 2023 and the third tranche would be available between January 1, 2024 and September 30, 2024, respectively. The Company’s ability to access these additional tranches was conditioned upon, among other things, the achievement of certain minimum revenue targets. Each term loan bore interest at a floating rate reset monthly based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 7.35% calculated on a 360 day basis (12.8% at September 30, 2023). Interest was payable monthly in arrears on the first day of each month. The first twenty-four (24) months of the term loans constituted an interest-only period (with a possible twelve (12) month extension). Subsequent to the interest-only period, the outstanding principal amount of the term loans was to be repayable in thirty-six (36) equal monthly payments (or twenty-four (24) with the extension). All remaining outstanding principal, together with all accrued and unpaid interest, was to be due at maturity on February 1, 2028. The term loans could be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the MidCap Credit Agreement. Additionally, the term loans were subject to mandatory prepayment fees, pursuant to the terms of the MidCap Credit Agreement. Prepayments of the term loans are subject to fees of 3%, 2%, and 1% of the prepayment amounts made during the first year, second year, and thereafter, respectively. At the time of the final payment of the term loans, the Company was also obligated to pay an exit fee of 4% of the total amount funded thereunder. The exit fee was being accreted over the life of the MidCap Credit Agreement utilizing the effective interest method. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a prepayment fee of 3% and the full 4% exit fee with proceeds from the Perceptive Credit Agreement discussed below. As the MidCap Credit Agreement contained a subjective acceleration clause and the Company has experienced recurring losses, outstanding borrowings have been presented as a current liability in the accompanying condensed consolidated balance sheet as of September 30, 2023. Revolving Facility The Company could borrow, repay and reborrow under the revolving facility until February 1, 2028, at which time the facility would terminate and all outstanding amounts thereunder, including all accrued and unpaid interest, must have been repaid. Borrowings were limited to the lesser of the Company’s borrowing base and the revolving commitment of $10,000,000. In connection with the revolving facility, the Company was required to maintain a lockbox account for the benefit of MidCap. Funds deposited into the lockbox account were swept daily to MidCap and applied to outstanding borrowings under the revolving agreement 5 days after the receipt of the funds by MidCap. Any balances in excess of the revolving borrowings were promptly returned to the Company. Loans made under the revolving facility bore interest at a floating rate based on an adjusted one month SOFR plus 0.1%, subject to a floor of 2.5%, plus 4.00% calculated on a 360 day basis (9.4% at September 30, 2023). The Company was obligated to pay a fee equal to 0.5% per annum on the outstanding balance of the revolving loans and the average unused portion of the available revolving commitments, respectively. Additionally, if the revolving facility was terminated or reduced before maturity, the Company was subject to a deferred origination fee. Terminations and reductions of the commitments were subject to fees of 3%, 2%, and 1% of the terminated or reduced commitments during the first year, second year, and thereafter, respectively. The Company was also required to maintain a minimum balance of 30% of the lesser of the borrowing base or $10 million under the revolving facility. If the average outstanding balance for a month was less than the minimum balance, the Company paid a minimum balance fee for the difference between the minimum balance and the average outstanding balance for the month at the highest rate for the revolving loans during the month. For such loans, interest and fees were payable monthly on the first day of each month. In connection with the satisfaction of the MidCap Credit Agreement, the Company paid MidCap a deferred origination fee of 3% of the revolving commitment with proceeds from the Perceptive Credit Agreement discussed below. As of September 30, 2023, the Company had drawn no amounts on the revolving facility. As of September 30, 2023, the Company had approximately $7,800,000 available to be drawn on the revolving facility. As the MidCap Credit Agreement contained a subjective acceleration clause and the Company was required to maintain a lockbox, any amounts drawn on the revolving facility would be presented as a current liability in the consolidated balance sheet. Collateral The obligations of the Company under the MidCap Credit Agreement were secured by first priority liens on substantially all of its assets. Covenants The MidCap Credit Agreement contained customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions. The MidCap Credit Agreement also required the Company to satisfy certain financial covenants, including minimum trailing twelve (12) month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $49 million, $60 million and $70 million for 2023, 2024, and 2025, respectively. Additionally, the Company had to maintain a balance of $10 million in cash and cash equivalents during the duration of the MidCap Credit Agreement’s term. As of September 30, 2023, the Company was not in compliance with the minimum trailing twelve month net revenue financial covenant. As a result of the repayment of amounts outstanding under the MidCap Credit Agreement with proceeds from the Perceptive Credit Agreement discussed below, there were no implications to the Company from this event of noncompliance. Events of Default The MidCap Credit Agreement also contained customary Events of Default that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change. Upon the occurrence and during the continuance of an Event of Default under the MidCap Credit Agreement, the respective administrative agent, if requested by the respective lenders, could, among other things, (i) suspend or terminate commitments, as well as obligations of the relevant administrative agent and lenders, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The MidCap Credit Agreement provided that, under certain circumstances, a default interest rate would apply on all obligations under such agreement during the existence of an Event of Default, at a per annum rate equal to 2% in excess of the applicable interest rate. The Company bifurcated a derivative liability related to the potential acceleration triggered upon an event of default (contingent put option) and the supplemental interest upon an event of default features of the MidCap Credit Agreement. The bifurcated derivative is de minimis to the Company’s unaudited condensed consolidated financial statements. Issuance of Warrants In connection with the Company’s obligations under the MidCap Credit Agreement, the Company issued to a statutory trust of MidCap Financial warrants to purchase up to 250,000 shares of its common stock, par value $0.001, with an exercise price of $3.40 per share. The warrants have a 10 year term and can be exercised by issuing payment to the Company for the number of warrants exercised or exercised net by surrendering warrants with an intrinsic value equal to the cumulative exercise price of the warrants being exercised. The Company determined that these warrants meet the criteria for equity classification and included the proceeds allocated to the warrants, on a relative fair value basis, as a debt discount and additional paid-in capital in the accompanying condensed consolidated financial statements. Debt Issuance Costs In connection with entering into the MidCap Credit Agreement, the Company incurred debt issuance costs of approximately $1.8 million, comprised primarily of commissions paid to the financial advisor. These costs were allocated to the issued and unissued term loans and the revolving facility. The costs allocated to the issued term loan were being amortized using the effective interest method over the life of the loan. The costs allocated to the unissued term loans have been deferred and were being amortized over the life of the term loans starting at the issuance date. The Company recognized the deferred costs at the point that the Company’s rights to borrow on the term loans expired. The costs allocated to the revolving facility were to be recognized on a straight-line basis over the term of the MidCap Credit Agreement. The Company expects to recognize all unamortized costs in loss on extinguishment of the MidCap Credit Agreement. The costs allocated to the issued term loan have been presented as a reduction of the term loan in the accompanying unaudited condensed consolidated balance sheet. The costs allocated to the unissued term loans and the revolving facility have been presented in prepaid expenses and other current assets in the accompanying unaudited condensed consolidated balance sheet. PERCEPTIVE CREDIT AGREEMENT On November 8, 2023, the Company entered into a Credit and Guaranty Agreement (the “Perceptive Credit Agreement”), by and among the Company (as borrower), Apyx China Holding Corp. and Apyx Bulgaria EOOD, the Company’s wholly-owned subsidiaries (as subsidiary guarantors), and Perceptive Credit Holdings IV, LP (as initial lender and administrative agent)(“Perceptive”), and the lenders from time to time party thereto. The Perceptive Credit Agreement provides for a facility of up to $45 million, consisting of senior secured term loans. The Perceptive Credit Agreement provides for (i) an initial loan of $37.5 million and (ii) a delayed draw loan of $7.5 million. The Credit Agreement matures on November 8, 2028. Loans The initial loan of $37.5 million was fully funded on November 8, 2023, with approximately $11.0 million of the proceeds used to payoff the obligations under the MidCap Credit Agreement, including approximately $1.0 million of related prepayment penalties and exit fees, and $2.5 million for transaction fees and other expenses incurred in connection with the Perceptive Credit Agreement, which includes a 2% fee of the total facility payable to Perceptive at closing. The delayed draw loan is available until December 31, 2024, conditioned upon, among other things, the achievement of a minimum revenue target. After repayment of the MidCap Credit Agreement and payment of transaction fees and other expenses in connection with the Perceptive Credit Agreement, the net proceeds of these loans will be used for working capital and general corporate purposes. The initial loan and delayed draw loan bear interest at a floating rate based on one-month SOFR, subject to a floor of 5.0%, plus 7.0%. The first forty-eight (48) months of the loans constitute an interest-only period, with interest payable monthly on the last day of each month. Subsequent to the interest-only period, the outstanding principal amount of the loans is repayable in monthly payments of 3% of the outstanding balance on the payment date. All remaining outstanding principal, together with all accrued and unpaid interest, is due at maturity. The loans may be voluntarily prepaid in full, or in part, at any time, subject to terms and conditions set forth in the Perceptive Credit Agreement. Additionally, the loans are subject to mandatory prepayment obligations, pursuant to the terms of the Perceptive Credit Agreement. Prepayments of the loans are subject to fees of 10%, 9%, 6%, 4% and 2% of the prepayment amounts made during the first year, second year, third year, fourth year, and thereafter, respectively. Collateral The obligations of the Company under the Perceptive Credit Agreement are secured by first priority liens on substantially all of its assets. Covenants The Perceptive Credit Agreement contains customary affirmative and negative covenants, including covenants limiting the ability of the Company and its subsidiaries, among other things, to incur debt, grant liens, make distributions, enter certain restrictive agreements, pay or modify subordinated debt, dispose of assets, make investments and acquisitions, enter into certain transactions with affiliates, and undergo certain fundamental changes, in each case, subject to limitations and exceptions set forth in the Perceptive Credit Agreement. The Perceptive Credit Agreement also requires the Company to satisfy certain financial covenants, including minimum trailing twelve month net revenue targets relating to its Advanced Energy segment (tested quarterly), with year-end targets of $41.6 million, $57.0 million, $70.2 million, and $87.8 million for 2024, 2025, 2026, and 2027, respectively. Additionally, the Company must maintain a balance of $3 million in cash and cash equivalents during the duration of the Perceptive Credit Agreement’s term. Events of Default The Perceptive Credit Agreement also contains customary Events of Default (as defined in the Perceptive Credit Agreement) that include, among other things, certain payment defaults, cross defaults to certain other contracts and indebtedness, covenant defaults, inaccuracy of representations and warranties, bankruptcy and insolvency defaults, judgment defaults, change of control defaults, defaults related to the failure to remain registered with the Securities and Exchange Commission and listed for trading on the Nasdaq Stock Market, and any material adverse change. Upon the occurrence and during the continuance of an Event of Default under the Perceptive Credit Agreement, the administrative agent, if requested by the respective lenders, may, among other things, (i) terminate commitments, (ii) declare all outstanding obligations under the agreement (including principal and accrued and unpaid interest) immediately due and payable, and (iii) exercise the other rights and remedies provided for under the agreement. The Perceptive Credit Agreement provides that, under certain circumstances, a default interest rate will apply on all obligations upon the occurrence and during the existence of an Event of Default, at a per annum rate equal to 3% in excess of the applicable interest rate. Issuance of Warrants In connection with the Company’s initial loan under the Perceptive Credit Agreement, the Company issued Perceptive warrants to purchase up to 1,250,000 shares of its common stock, par value $0.001, with an exercise price of $2.43 per share. Upon the

CHINA JOINT VENTURE

CHINA JOINT VENTURE	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
CHINA JOINT VENTURE	CHINA JOINT VENTURE In 2019, the Company executed a joint venture agreement with its Chinese supplier (the “China JV”) whereby the Company has a 51% interest. The China JV has been consolidated in these condensed consolidated financial statements. The agreement required the Company to make capital contributions into the newly formed entity of approximately $357,000, of which approximately $203,000 and $154,000, respectively, were contributed during the years ended December 31, 2021 and 2020. In June 2023, the Company executed an amendment to the joint venture agreement to increase the amount of it’s registered capital. The amendment requires the Company to make additional capital contributions to the China JV of $255,000, of which $153,000 has been made as of September 30, 2023. As of the date of these condensed consolidated financial statements, the joint venture has not commenced principal operations. Changes in the Company ’ s ownership investment in the China JV were as follows: Three Months Ended September 30, Nine Months Ended (In thousands) 2023 2022 2023 2022 Beginning interest in China JV $ 142 $ 269 $ 219 $ 317 Contributions $ 153 $ — $ 153 $ — Net loss attributable to Apyx $ (48) $ (33) $ (125) $ (81) Ending interest in China JV $ 247 $ 236 $ 247 $ 236

EARNINGS (LOSS) PER SHARE

EARNINGS (LOSS) PER SHARE	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE	EARNINGS (LOSS) PER SHARE Basic earnings (loss) per share (“basic EPS”) is computed by dividing the net income or loss by the weighted average number of common shares outstanding for the reporting period. Diluted earnings (loss) per share (“diluted EPS”) gives effect to all dilutive potential shares outstanding. As the Company is in a net loss position for all periods presented, all potential shares outstanding are anti-dilutive. The following table provides the computation of basic and diluted loss per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2023 2022 2023 2022 Numerator: Net loss attributable to stockholders $ (4,629) $ (5,764) $ (9,106) $ (17,135) Denominator: Weighted average shares outstanding - basic and diluted 34,642 34,569 34,614 34,488 Loss per share: Basic and diluted $ (0.13) $ (0.17) $ (0.26) $ (0.50) Anti-dilutive instruments excluded from diluted loss per common share: Options 7,713 6,635 7,713 6,635 Warrants 250 — 250 —

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize. The Company recognized approximately $1,351,000 and $4,200,000, respectively, in stock-based compensation expense during the three and nine months ended September 30, 2023, as compared with $1,692,000 and $5,056,000, respectively, for the three and nine months ended September 30, 2022. Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2022 6,520,444 $ 7.12 Granted 1,527,865 2.63 Exercised (57,000) 2.65 Canceled and forfeited (278,546) 7.03 Outstanding at September 30, 2023 7,712,763 $ 6.27 The Company allows stock option holders to exercise stock-based awards by surrendering stock-based awards with an intrinsic value equal to the cumulative exercise price of the stock-based awards being exercised, referred to as net settlements. These surrenders are included in stock options exercised in the options rollforward above. For the three months ended September 30, 2023 and 2022, respectively, we received 6,662 and 55,853 options as payment in the exercise of 5,338 and 33,313 options. For the nine months ended September 30, 2023 and 2022, respectively, we received 10,967 and 92,520 options as payment in the exercise of 11,033 and 72,313 options. Common shares required to be issued upon the exercise of stock options would be issued from authorized and unissued shares. The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model. 2023 Grants Strike price $2.50 - $4.21 Risk-free rate 3.6% - 4.3% Expected dividend yield — Expected volatility 85.8% - 88.4% Expected term (in years) 6

INCOME TAXES

INCOME TAXES	9 Months Ended
	Sep. 30, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES Income tax (benefit) expense was approximately $(318,000) and $50,000 with effective tax rates of 6.4% and (0.9)% for the three months ended September 30, 2023 and 2022, respectively. For the three months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to interest income on the Company's income tax refund that it received during the quarter, partially offset by the full valuation allowance recorded on the net operating loss (“NOL”) generated during the period. For the three months ended September 30, 2022, the effective rate differs from the statutory rate primarily due to the full valuation allowance recorded on the NOL generated during the period. Income tax (benefit) expense was approximately $(2,519,000) and $216,000 with effective tax rates of 21.4% and (1.3)% for the nine months ended September 30, 2023 and 2022, respectively. For the nine months ended September 30, 2023, the effective rate differs from the statutory rate primarily due to the reversal of the Company’s liability for uncertain tax positions, including accrued interest and penalties, of approximately $2.1 million, which were sustained upon the completion in January 2023 of the IRS examination of the Company's 2018 through 2020 income tax returns and interest income on the Company's

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	9 Months Ended
	Sep. 30, 2023
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation The medical device industry is characterized by frequent claims and litigation, and the Company may become subject to various claims, lawsuits and proceedings in the ordinary course of our business. Such claims may include claims by current or former employees, distributors and competitors, claims concerning the marketing and promotion of our products and product liability claims. The Company is involved in a number of legal actions relating to the use of our Helium Plasma technology. The outcomes of these legal actions are not within the Company’s control and may not be known for prolonged periods of time. It believes that such claims are adequately covered by insurance; however, in the case of one of the Company’s carriers, the Company is in a dispute regarding the total level of coverage available. Notwithstanding the foregoing, in the opinion of management, the Company has meritorious defenses, and such claims are not expected, individually or in the aggregate, to result in a material, adverse effect on its financial condition, results of operations and cash flows. However, in the event that damages exceed the aggregate coverage limits of the Company’s policies or if its insurance carriers disclaim coverage, management believes it is possible that costs associated with these claims could have a material adverse impact on the consolidated financial condition, results of operations and cash flows. During December 2021, the Company provided notice of contract termination to an international distributor of the Company. In March 2022, the Company received a letter from the former distributor citing improper contract termination and alleging damages. During 2022, the Company recorded an estimated loss of $250,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. The Company has not experienced any movement on the matter since our response to the distributor in the fourth quarter of 2022. Accordingly, we have revised our estimated loss on the matter to $0 as it is no longer probable that a loss has been incurred. The reduction in estimated loss of $250,000 is included in professional services in the accompanying Condensed Consolidated Statements of Operations for the nine months ended September 30, 2023. As previously disclosed with the U.S. Securities and Exchange Commission on the Company’s Current Report on Form 8-K filed June 7, 2022, on June 6, 2022, a complaint (the “Hattaway Complaint”) was filed in the United States District Court for the Middle District of Florida (the “U.S. District Court”) by plaintiff William E. Hattaway, individually and on behalf of all others similarly situated against the Company, Charles D. Goodwin (“Goodwin”), the Company’s President and Chief Executive Officer and a member of the Company’s Board of Directors, and Tara Semb (“Semb”), the Company’s Chief Financial Officer, Treasurer and Secretary, alleging violations by the Company, Goodwin and Semb of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 thereunder, primarily related to certain public statements and disclosures concerning the off-label usage of certain of the Company’s Advanced Energy products and the impact such usage would have on the Company’s business, operations and prospects. The Hattaway Complaint sought an unspecified amount of damages. While the matter was in the early stages, management had determined that a loss was probable in the estimated range of $475,000 to $2,500,000. The Company recorded an estimated loss of $475,000 in professional services in the accompanying Condensed Consolidated Statement of Operations for the nine months ended September 30, 2022. On June 15, 2023, the U.S. District Court issued an Order dismissing the Hattaway Complaint and granting plaintiff until July 3, 2023 to file a second amended complaint, failing which the U.S. District Court would close the case. On June 27, 2023, the Plaintiff formally notified the Court that a Second Amended Complaint will not be filed and on July 17, 2023, the case was marked closed based on the Court’s June 15 dismissal order. This closed the matter for the estimated loss recorded by the Company. During 2022, the Company was notified of certain procedures alleged to have been performed by the same physician and which are currently the subject of two related products liability cases within the courts. Subsequent to year end, the Company was notified by its insurance carriers that all or most of the ten individual plaintiff’s allegations could be subject to separate deductibles notwithstanding the commonality of each underlying occurrence. The Company has determined that a loss is probable and that a range of estimated losses is approximately $1,450,000 to $2,400,000. The Company recorded an estimated loss of $1,450,000 related to the matters during 2022. It is at least possible that a change in the actual amount of loss will occur in the near term, though management expects the actual amount of loss will be within the estimated range of losses. On March 1, 2023, Shiva Stein as plaintiff filed a derivative complaint in the Court of Chancery of the State of Delaware, captioned Stein v. Makrides, et al., C.A. No. 2023-0239-MTZ (the “Stein Suit”) against individual members of the Company’s board of directors and naming the Company as a nominal defendant, primarily concerning the facts at issue in a previously disclosed federal securities class action lawsuit filed in 2019 and settled in 2020, captioned Pritchard v. Apyx Medical Corporation, et al., Case No. 8:19-cv-00919 (M.D. Fla.) (the “Pritchard Case”). The Stein Suit sought unspecified damages alleged to have resulted from purported breaches of fiduciary duty, unjust enrichment and related claims based on the same set of allegedly misleading statements and material omissions described in the settled Pritchard Case, which concerned the 2018-2019 clinical study conducted by the Company to evaluate the safety and efficacy of its J-Plasma technology for dermal resurfacing. On April 3, 2023, the Company formally moved to dismiss the case as time-barred and on other legal grounds, which triggered the plaintiff’s right to file an amended complaint. On July 12, 2023, plaintiff’s counsel informed the Company’s counsel that plaintiff Stein did not intend to file an amended complaint, and on July 17, 2023 plaintiff’s counsel filed a notice of voluntary dismissal. An order of the Court dismissing the Stein Suit, with prejudice, was entered on July 20, 2023. The Company accrues a liability in its consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate than any other, the minimum amount of the range is recorded. If a loss is reasonably possible, but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed in the notes to the condensed consolidated financial statements. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded, actual results may differ from these estimates. Purchase Commitments At September 30, 2023, the Company had purchase commitments totaling approximately $3.5 million, substantially all of which is expected to be purchased within the next twelve months.

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	9 Months Ended
	Sep. 30, 2023
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	RELATED PARTY TRANSACTIONS Several relatives of Nikolay Shilev, Apyx Bulgaria’s Managing Director, are considered related parties. Teodora Shileva, Mr. Shilev’s spouse, is an employee of the Company working in the accounting department. Svetoslav Shilev, Mr. Shilev’s son, is a quality manager in the quality assurance department. The partner in the Company's China joint venture is also a supplier to the Company. For the three months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $50,000 and $85,000, respectively. For the nine months ended September 30, 2023 and 2022, the Company made purchases from this supplier of approximately $501,000 and $455,000, respectively. At September 30, 2023 and December 31, 2022, respectively, the Company had net payables to and receivables from this supplier approximately $12,000 and $8,000, respectively.

GEOGRAPHIC AND SEGMENT INFORMAT

GEOGRAPHIC AND SEGMENT INFORMATION	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
GEOGRAPHIC AND SEGMENT INFORMATION	GEOGRAPHIC AND SEGMENT INFORMATION Operating segments are aggregated into reportable segments only if they exhibit similar economic characteristics. In addition to similar economic characteristics, the Company also considers the following factors in determining the reportable segments: the nature of business activities, the management structure directly accountable to its chief operating decision maker for operating and administrative activities, availability of discrete financial information and information presented to the Board of Directors and investors. Asset information is not reviewed by the chief operating decision maker by segment and is not available by segment, accordingly, the Company has not presented a measure of assets by segment. The Company ’ s reportable segments are disclosed as principally organized and managed as two operating segments: Advanced Energy and OEM. “ Corporate & Other ” includes certain unallocated corporate and administrative costs which were not specifically attributed to any reportable segment. The OEM segment is primarily development and manufacturing contract and product driven, all related expenses are recorded as cost of sales, therefore no segment specific operating expenses are incurred. Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2023 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 9,836 $ 2,140 $ — $ 11,976 Income (loss) from operations 70 591 (5,298) (4,637) Interest income — — 248 248 Interest expense — — (585) (585) Other loss, net — — (19) (19) Income tax benefit — — (318) (318) Three Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 7,080 $ 2,034 $ — $ 9,114 (Loss) income from operations (1,174) 356 (4,964) (5,782) Interest income — — 73 73 Interest expense — — (1) (1) Other loss, net — — (35) (35) Income tax expense — — 50 50 Nine Months Ended September 30, 2023 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 31,248 $ 6,439 $ — $ 37,687 (Loss) income from operations (509) 1,795 (12,769) (11,483) Interest income — — 478 478 Interest expense — — (1,362) (1,362) Other income, net — — 622 622 Income tax benefit — — (2,519) (2,519) Nine Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 26,258 $ 5,641 $ — $ 31,899 (Loss) income from operations (3,765) 1,142 (15,006) (17,629) Interest income — — 93 93 Interest expense — — (12) (12) Other income, net — — 551 551 Income tax expense — — 216 216 International sales represented approximately 27.8% and 26.6% of total revenues for the three and nine months ended September 30, 2023, respectively, as compared with approximately 23.2% and 29.5% of total revenues for the three and nine months ended September 30, 2022, respectively. Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Sales by Domestic and International Domestic $ 8,652 $ 6,997 $ 27,660 $ 22,492 International 3,324 2,117 10,027 9,407 Total $ 11,976 $ 9,114 $ 37,687 $ 31,899

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	9 Months Ended
	Sep. 30, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Recent Accounting Pronouncements	In June 2016, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2016-13, Financial Instruments—Credit Losses (Topic 326). The update changes the impairment model for most financial assets and certain other instruments, including trade and other receivables, contract assets, held-to-maturity debt securities and loans, and requires entities to use a new forward-looking expected loss model that will result in the earlier recognition of allowance for losses. This update, as originally issued, was effective for annual and interim periods beginning after December 15, 2019, with early adoption permitted. In November 2019, the FASB issued ASU 2019-10, Financial Instruments - Credit Losses (Topic 326), Derivatives and Hedging (Topic 815), and Leases (Topic 842) Effective Dates , which deferred the effective dates of these standards for Smaller Reporting Companies until fiscal years beginning after December 15, 2022. The Company adopted the new standard on January 1, 2023 and its impact was not material to the Company. No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material impact on our consolidated financial statements or disclosures.
Inventories	Inventories are stated at the lower of cost or net realizable value. Cost is determined on a first in, first out basis. Finished goods and work-in-process inventories include material, labor and overhead costs. Factory overhead costs are primarily allocated to inventory manufactured in-house based upon direct labor hours.
Share based compensation	Under the Company’s stock option plans, the Board of Directors may grant restricted stock and options to purchase common shares to the Company's employees, officers, directors and consultants. The Company accounts for stock options in accordance with FASB ASC Topic 718, Compensation - Stock Compensation , with stock-based compensation expense recognized over the vesting period based on the fair value on the grant date utilizing the Black-Scholes model, which includes a number of estimates that affect the grant date fair value and the amount of expense to recognize.

INVENTORIES (Tables)

INVENTORIES (Tables)	9 Months Ended
	Sep. 30, 2023
Inventory Disclosure [Abstract]
Schedule of inventory	Inventories consisted of the following: (In thousands) September 30, December 31, Raw materials $ 4,578 $ 4,979 Work in process 2,522 2,160 Finished goods 4,796 5,115 Gross inventories 11,896 12,254 Less: provision for obsolescence (611) (457) Inventories, net $ 11,285 $ 11,797

PROPERTY AND EQUIPMENT (Tables)

PROPERTY AND EQUIPMENT (Tables)	9 Months Ended
	Sep. 30, 2023
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	(In thousands) September 30, 2023 December 31, Land $ — $ 1,600 Building and improvements — 4,426 Machinery and equipment 2,635 2,613 Furniture and fixtures 216 211 Computer equipment and software 1,079 1,420 Leasehold improvements 178 178 Molds 1,017 847 Total property, plant and equipment 5,125 11,295 Less: accumulated depreciation and amortization (3,489) (5,041) Property and equipment in service 1,636 6,254 Construction in progress 457 507 Property and equipment, net $ 2,093 $ 6,761

LEASES (Tables)

LEASES (Tables)	9 Months Ended
	Sep. 30, 2023
Leases [Abstract]
Lease Costs	Information about the Company’s weighted average remaining operating lease terms and discount rate assumptions are as follows: September 30, 2023 December 31, Weighted average remaining lease term (in years) 9.2 4.4 Weighted average discount rate 8.42% 2.54%
Maturities of Operating Lease Liabilities	Maturities of operating lease liabilities as of September 30, 2023 are as follows: (In thousands) 2023 $ 190 2024 773 2025 799 2026 826 2027 855 Thereafter 4,516 Total lease payments 7,959 Less imputed interest (2,657) Present value of lease liabilities 5,302 Less current portion of lease liabilities (310) Long-term portion of lease liabilities $ 4,992

ACCRUED EXPENSES AND OTHER CU_2

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Tables)	9 Months Ended
	Sep. 30, 2023
Payables and Accruals [Abstract]
Schedule of Accounts Payable and Accrued Liabilities	Accrued expenses and other current liabilities consisted of the following: (in thousands) September 30, December 31, Accrued payroll $ 879 $ 563 Accrued bonuses 1,188 — Accrued commissions 1,183 847 Accrued product warranties 386 391 Accrued product liability claim insurance deductibles 2,060 1,825 Accrued professional fees and legal related contingent liabilities 607 901 Joint and several payroll liability — 345 Short-term contract liabilities 712 853 Uncertain tax positions — 2,079 Sales tax payable 245 245 Other accrued expenses and current liabilities 654 879 Total accrued expenses and other current liabilities $ 7,914 $ 8,928

DEBT (Tables)

DEBT (Tables)	9 Months Ended
	Sep. 30, 2023
Debt Disclosure [Abstract]
Term Loan	The Company’s term loan, net consists of the following at September 30, 2023: (In thousands) Term loan $ 10,000 Unamortized debt issuance costs (414) Unamortized debt discount, including accretion of exit fee (577) Term loan, net $ 9,009

CHINA JOINT VENTURE (Tables)

CHINA JOINT VENTURE (Tables)	9 Months Ended
	Sep. 30, 2023
Noncontrolling Interest [Abstract]
Schedule of China Joint Venture	Changes in the Company ’ s ownership investment in the China JV were as follows: Three Months Ended September 30, Nine Months Ended (In thousands) 2023 2022 2023 2022 Beginning interest in China JV $ 142 $ 269 $ 219 $ 317 Contributions $ 153 $ — $ 153 $ — Net loss attributable to Apyx $ (48) $ (33) $ (125) $ (81) Ending interest in China JV $ 247 $ 236 $ 247 $ 236

EARNINGS (LOSS) PER SHARE (Tabl

EARNINGS (LOSS) PER SHARE (Tables)	9 Months Ended
	Sep. 30, 2023
Earnings Per Share [Abstract]
Basic and diluted earnings (loss) per share	The following table provides the computation of basic and diluted loss per share. Three Months Ended Nine Months Ended (in thousands, except per share data) 2023 2022 2023 2022 Numerator: Net loss attributable to stockholders $ (4,629) $ (5,764) $ (9,106) $ (17,135) Denominator: Weighted average shares outstanding - basic and diluted 34,642 34,569 34,614 34,488 Loss per share: Basic and diluted $ (0.13) $ (0.17) $ (0.26) $ (0.50) Anti-dilutive instruments excluded from diluted loss per common share: Options 7,713 6,635 7,713 6,635 Warrants 250 — 250 —

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	9 Months Ended
	Sep. 30, 2023
Share-Based Payment Arrangement [Abstract]
Summary of stock options and stock awards	Stock option activity is summarized as follows: Number of options Weighted average exercise price Outstanding at December 31, 2022 6,520,444 $ 7.12 Granted 1,527,865 2.63 Exercised (57,000) 2.65 Canceled and forfeited (278,546) 7.03 Outstanding at September 30, 2023 7,712,763 $ 6.27
Schedule of option fair value assumptions	The Company calculated the grant date fair value of options granted in 2023 (“2023 Grants”) utilizing a Black-Scholes model. 2023 Grants Strike price $2.50 - $4.21 Risk-free rate 3.6% - 4.3% Expected dividend yield — Expected volatility 85.8% - 88.4% Expected term (in years) 6

GEOGRAPHIC AND SEGMENT INFORM_2

GEOGRAPHIC AND SEGMENT INFORMATION (Tables)	9 Months Ended
	Sep. 30, 2023
Segment Reporting [Abstract]
Schedule of reporting information by segment	Summarized financial information with respect to reportable segments is as follows: Three Months Ended September 30, 2023 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 9,836 $ 2,140 $ — $ 11,976 Income (loss) from operations 70 591 (5,298) (4,637) Interest income — — 248 248 Interest expense — — (585) (585) Other loss, net — — (19) (19) Income tax benefit — — (318) (318) Three Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 7,080 $ 2,034 $ — $ 9,114 (Loss) income from operations (1,174) 356 (4,964) (5,782) Interest income — — 73 73 Interest expense — — (1) (1) Other loss, net — — (35) (35) Income tax expense — — 50 50 Nine Months Ended September 30, 2023 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 31,248 $ 6,439 $ — $ 37,687 (Loss) income from operations (509) 1,795 (12,769) (11,483) Interest income — — 478 478 Interest expense — — (1,362) (1,362) Other income, net — — 622 622 Income tax benefit — — (2,519) (2,519) Nine Months Ended September 30, 2022 (In thousands) Advanced Energy OEM Corporate & Other Total Sales $ 26,258 $ 5,641 $ — $ 31,899 (Loss) income from operations (3,765) 1,142 (15,006) (17,629) Interest income — — 93 93 Interest expense — — (12) (12) Other income, net — — 551 551 Income tax expense — — 216 216
Schedule of revenue by geographic area	Revenue by geographic region, based on the customer's “ship to” location on the invoice, are as follows: Three Months Ended Nine Months Ended (In thousands) 2023 2022 2023 2022 Sales by Domestic and International Domestic $ 8,652 $ 6,997 $ 27,660 $ 22,492 International 3,324 2,117 10,027 9,407 Total $ 11,976 $ 9,114 $ 37,687 $ 31,899

BASIS OF PRESENTATION (Details)

BASIS OF PRESENTATION (Details) - USD ($) $ in Thousands

1 Months Ended

3 Months Ended

9 Months Ended

12 Months Ended

Aug. 10, 2023

May 08, 2023

Mar. 14, 2023

Jan. 09, 2023

Nov. 22, 2022

Jan. 31, 2023

Sep. 30, 2023

Sep. 30, 2022

Sep. 30, 2023

Sep. 30, 2022

Dec. 31, 2022

Dec. 31, 2018

Nov. 08, 2023

Feb. 17, 2023

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Proceeds from the disposition of Core business

$ 97,000

Loss from operations

$ 4,637

$ 5,782

$ 11,483

$ 17,629

$ 23,600

Net cash used in cash operations

3,037

15,750

Cash used in operations

11,100

20,300

Cash and cash equivalents

22,134

22,134

$ 10,192

Cash and cash equivalents balance

$ 10,000

10,000

$ 10,000

Purchase agreement

$ 7,650

Leaseback term

10 years

Income tax receivables

$ 200

(7,545)

$ (97)

Proceeds from income tax refunds

$ 8,100

$ 8,100

Proceeds from income tax refund, interest

400

Proceeds from income tax refund, principal

$ 7,700

Number of positions eliminated

14%

Subsequent Event

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Cash and cash equivalents balance

$ 3,000

MidCap Credit Agreement

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Credit facility

35,000

MidCap Credit Agreement | Line of Credit

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Credit facility

35,000

MidCap Credit Agreement | Line of Credit | Secured Debt

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Mortgage loan, principal amount

25,000

MidCap Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche One

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Mortgage loan, principal amount

10,000

MidCap Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Two

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Mortgage loan, principal amount

5,000

MidCap Credit Agreement | Line of Credit | Secured Debt | Debt Instrument, Covenant, Tranche Three

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Mortgage loan, principal amount

10,000

MidCap Credit Agreement | Line of Credit | Revolving Credit Facility

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Credit facility

$ 10,000

Perceptive Credit Agreement | Line of Credit | Subsequent Event

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Credit facility

45,000

Perceptive Credit Agreement, Initial Loan | Line of Credit | Subsequent Event

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Credit facility

37,500

Perceptive Credit Agreement, Delayed Draw Loan | Line of Credit | Subsequent Event

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Credit facility

$ 7,500

Shelf Registration

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Securities registered, new issues

$ 100,000

At-The-Market

Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]

Securities registered, new issues

$ 40,000

INVENTORIES (Details)

INVENTORIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Inventory Disclosure [Abstract]
Raw materials	$ 4,578	$ 4,979
Work in process	2,522	2,160
Finished goods	4,796	5,115
Gross inventories	11,896	12,254
Less: provision for obsolescence	(611)	(457)
Inventories, net	$ 11,285	$ 11,797

PROPERTY AND EQUIPMENT - Schedu

PROPERTY AND EQUIPMENT - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 5,125	$ 11,295
Less: accumulated depreciation and amortization	(3,489)	(5,041)
Property and equipment in service	1,636	6,254
Construction in progress	457	507
Property and equipment, net	2,093	6,761
Land
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	0	1,600
Building and improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	0	4,426
Machinery and equipment
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	2,635	2,613
Furniture and fixtures
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	216	211
Computer equipment and software
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	1,079	1,420
Leasehold improvements
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	178	178
Molds
Property, Plant and Equipment [Line Items]
Total property, plant and equipment	$ 1,017	$ 847

PROPERTY AND EQUIPMENT - Narrat

PROPERTY AND EQUIPMENT - Narrative (Details) - USD ($) $ in Thousands			3 Months Ended		9 Months Ended
	May 08, 2023	Mar. 14, 2023	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Property, Plant and Equipment [Abstract]
Purchase agreement		$ 7,650
Leaseback term	10 years
Sale leaseback, net cash proceeds	$ 6,600
Sale leaseback, security deposit withheld	$ 600
Security deposit equal to annual rent	1 year
Gain on sale-leaseback			$ 0	$ 0	$ 2,692	$ 0

LEASES - Narrative (Details)

LEASES - Narrative (Details)	1 Months Ended
	May 31, 2023 USD ($)
Leases [Abstract]
Sale leaseback, term of lease	10 years
Sale leaseback, renewal term	5 years
Sale leaseback, annual rent payment	$ 619,500
Sale leaseback, annual rent increase	4%
Sale leaseback, management fee on rent payment	3%

LEASES - Lease Terms and Discou

LEASES - Lease Terms and Discount Rates (Details)	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
Weighted average remaining lease term	9 years 2 months 12 days	4 years 4 months 24 days
Weighted average discount rate	8.42%	2.54%

LEASES - Maturities of Lease Li

LEASES - Maturities of Lease Liabilities (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Leases [Abstract]
2023	$ 190
2024	773
2025	799
2026	826
2027	855
Thereafter	4,516
Total lease payments	7,959
Less imputed interest	(2,657)
Present value of lease liabilities	5,302
Less current portion of lease liabilities	(310)	$ (216)
Long-term portion of lease liabilities	$ 4,992	$ 470

ACCRUED EXPENSES AND OTHER CU_3

ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES (Details) - USD ($) $ in Thousands	Sep. 30, 2023	Dec. 31, 2022
Payables and Accruals [Abstract]
Accrued payroll	$ 879	$ 563
Accrued bonuses	1,188	0
Accrued commissions	1,183	847
Accrued product warranties	386	391
Accrued product liability claim insurance deductibles	2,060	1,825
Accrued professional fees and legal related contingent liabilities	607	901
Joint and several payroll liability	0	345
Short-term contract liabilities	712	853
Uncertain tax positions	0	2,079
Sales tax payable	245	245
Other accrued expenses and current liabilities	654	879
Total accrued expenses and other current liabilities	$ 7,914	$ 8,928

DEBT - Term Loan (Details)

DEBT - Term Loan (Details) - Secured Debt - Term Loan $ in Thousands	Sep. 30, 2023 USD ($)
Debt Instrument [Line Items]
Term loan	$ 10,000
Unamortized debt issuance costs	(414)
Unamortized debt discount, including accretion of exit fee	(577)
Term loan, net	$ 9,009

DEBT - Narrative (Details)

DEBT - Narrative (Details) $ / shares in Units, $ in Thousands			3 Months Ended	9 Months Ended
	Nov. 08, 2023 USD ($) $ / shares shares	Feb. 17, 2023 USD ($) monthlyPayment $ / shares shares	Sep. 30, 2023 USD ($) $ / shares	Sep. 30, 2023 USD ($) $ / shares	Dec. 31, 2022 $ / shares
Debt Instrument [Line Items]
Twelve month net revenue target, year one		$ 49,000
Twelve month net revenue target, year two		60,000
Twelve month net revenue target, year three		70,000
Cash and cash equivalents balance		$ 10,000	$ 10,000	$ 10,000
Warrants (in shares) | shares		250,000
Common stock, par value (in dollars per share) | $ / shares		$ 0.001	$ 0.001	$ 0.001	$ 0.001
Warrants, exercise price (in dollars per share) | $ / shares		$ 3.40
Warrants term		10 years
Debt issuance costs		$ 1,800
Subsequent Event
Debt Instrument [Line Items]
Twelve month net revenue target, year one	$ 41,600
Twelve month net revenue target, year two	57,000
Twelve month net revenue target, year three	70,200
Cash and cash equivalents balance	$ 3,000
Warrants (in shares) | shares	1,250,000
Common stock, par value (in dollars per share) | $ / shares	$ 0.001
Warrants, exercise price (in dollars per share) | $ / shares	$ 2.43
Twelve month net revenue target, year four	$ 87,800
Warrants to be issued | shares	250,000
MidCap Credit Agreement
Debt Instrument [Line Items]
Credit facility		35,000
Line of Credit | MidCap Credit Agreement
Debt Instrument [Line Items]
Loss on extinguishment of debt				$ 2,500
Credit facility		$ 35,000
Default, applicable interest rate		2%
Line of Credit | MidCap Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Repayments of lines of credit	$ 11,000
Prepayment penalties and exit fees	1,000
Transaction cost and other expenses	2,500
Line of Credit | MidCap Credit Agreement | Secured Debt
Debt Instrument [Line Items]
Amortization of debt issuance costs			$ 36	87
Amortization of debt discounts			$ 81	$ 198
Mortgage loan, principal amount		$ 25,000
Interest rate floor		2.50%
Interest rate floor spread		7.35%
Period of interest only		24 months
Extension period		12 months
Number of monthly payments | monthlyPayment		36
Number of monthly payments, extension | monthlyPayment		24
Exit fee		4%
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period One
Debt Instrument [Line Items]
Prepayment fee		3%
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Two
Debt Instrument [Line Items]
Prepayment fee		2%
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Prepayment Period Three
Debt Instrument [Line Items]
Prepayment fee		1%
Line of Credit | MidCap Credit Agreement | Secured Debt | Adjusted Term Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Variable rate		0.10%
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche One
Debt Instrument [Line Items]
Mortgage loan, principal amount		$ 10,000
Effective interest rate			12.80%	12.80%
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Two
Debt Instrument [Line Items]
Mortgage loan, principal amount		5,000
Line of Credit | MidCap Credit Agreement | Secured Debt | Debt Instrument, Covenant, Tranche Three
Debt Instrument [Line Items]
Mortgage loan, principal amount		10,000
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility
Debt Instrument [Line Items]
Amortization of debt issuance costs			$ 25	$ 62
Amortization of debt discounts			3	7
Credit facility		$ 10,000
Interest rate floor		2.50%
Interest rate floor spread		4%
Annual fee		0.50%
Remaining borrowing capacity			$ 7,800	$ 7,800
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period One
Debt Instrument [Line Items]
Effective interest rate			9.40%	9.40%
Borrowing base, minimum balance		$ 10,000
Lockbox account, funds to be applied to borrowings		5 days
Termination fees		3%
Borrowing base, minimum balance		30%
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Two
Debt Instrument [Line Items]
Termination fees		2%
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Debt Instrument, Termination Period Three
Debt Instrument [Line Items]
Termination fees		1%
Line of Credit | MidCap Credit Agreement | Revolving Credit Facility | Adjusted Term Secured Overnight Financing Rate (SOFR)
Debt Instrument [Line Items]
Variable rate		0.10%
Line of Credit | Perceptive Credit Agreement | Subsequent Event
Debt Instrument [Line Items]
Credit facility	$ 45,000
Interest rate floor	5%
Interest rate floor spread	7%
Period of interest only	48 months
Default, applicable interest rate	3%
Commitment fee percentage	2%
Principal payments, percentage	3%
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period One | Subsequent Event
Debt Instrument [Line Items]
Prepayment fee	10%
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period Two | Subsequent Event
Debt Instrument [Line Items]
Prepayment fee	9%
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period Three | Subsequent Event
Debt Instrument [Line Items]
Prepayment fee	6%
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period Four | Subsequent Event
Debt Instrument [Line Items]
Prepayment fee	4%
Line of Credit | Perceptive Credit Agreement | Debt Instrument, Prepayment Period, After Year Four | Subsequent Event
Debt Instrument [Line Items]
Prepayment fee	2%
Line of Credit | Perceptive Credit Agreement, Initial Loan | Subsequent Event
Debt Instrument [Line Items]
Credit facility	$ 37,500
Proceeds from line of credit	37,500
Line of Credit | Perceptive Credit Agreement, Delayed Draw Loan | Subsequent Event
Debt Instrument [Line Items]
Credit facility	$ 7,500

CHINA JOINT VENTURE - Narrative

CHINA JOINT VENTURE - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		4 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2023	Dec. 31, 2019
Noncontrolling Interest [Line Items]
Contributions from non-controlling interest	$ 147			$ 147
Corporate Joint Venture
Noncontrolling Interest [Line Items]
Required capital contribution								$ 255	$ 357
Contributions from non-controlling interest	$ 153	$ 0	$ 153	$ 153	$ 0	$ 203	$ 154
Chinese Supplier
Noncontrolling Interest [Line Items]
Ownership interest									51%

CHINA JOINT VENTURE - Rollforwa

CHINA JOINT VENTURE - Rollforward of Joint Venture (Details) - USD ($) $ in Thousands	3 Months Ended		4 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV				$ 211
Contributions	$ 147			147
Net loss attributable to Apyx	(46)	$ (31)		(120)	$ (78)
Ending interest in China JV	238		$ 238	238
Corporate Joint Venture
Stockholders' Equity Attributable to Noncontrolling Interest [Roll Forward]
Beginning interest in China JV	142	269		219	317
Contributions	153	0	153	153	0	$ 203	$ 154
Net loss attributable to Apyx	(48)	(33)		(125)	(81)
Ending interest in China JV	$ 247	$ 236	$ 247	$ 247	$ 236	$ 317

EARNINGS (LOSS) PER SHARE (Deta

EARNINGS (LOSS) PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Earnings Per Share Reconciliation [Abstract]
Net loss attributable to stockholders, basic	$ (4,629)	$ (5,764)	$ (9,106)	$ (17,135)
Net loss attributable to stockholders, diluted	$ (4,629)	$ (5,764)	$ (9,106)	$ (17,135)
Denominator:
Weighted average shares outstanding - basic (in shares)	34,642	34,569	34,614	34,488
Weighted average shares outstanding - diluted (in shares)	34,642	34,569	34,614	34,488
Loss per share:
Basic (in dollars per share)	$ (0.13)	$ (0.17)	$ (0.26)	$ (0.50)
Diluted (in dollars per share)	$ (0.13)	$ (0.17)	$ (0.26)	$ (0.50)
Options
Anti-dilutive instruments excluded from diluted loss per common share:
Anti-dilutive instruments (in shares)	7,713	6,635	7,713	6,635
Warrants
Anti-dilutive instruments excluded from diluted loss per common share:
Anti-dilutive instruments (in shares)	250	0	250	0

STOCK-BASED COMPENSATION - Narr

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Share-Based Payment Arrangement [Abstract]
Stock based compensation	$ 1,351	$ 1,692	$ 4,200	$ 5,056
Stock swaps equity instruments received (in shares)	6,662	55,853	10,967	92,520
Stock swaps (in shares)	5,338	33,313	11,033	72,313

STOCK-BASED COMPENSATION - Summ

STOCK-BASED COMPENSATION - Summary of Stock Options (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares shares
Number of options
Outstanding, beginning of period (in shares) | shares	6,520,444
Granted (in shares) | shares	1,527,865
Exercised (in shares) | shares	(57,000)
Canceled and forfeited (in shares) | shares	(278,546)
Outstanding, end of period (in shares) | shares	7,712,763
Weighted average exercise price
Outstanding, beginning of period (in dollars per share) | $ / shares	$ 7.12
Granted (in dollars per share) | $ / shares	2.63
Exercised (in dollars per share) | $ / shares	2.65
Canceled and forfeited (in dollars per shares) | $ / shares	7.03
Outstanding, end of period (in dollars per share) | $ / shares	$ 6.27

STOCK-BASED COMPENSATION - Fair

STOCK-BASED COMPENSATION - Fair Value Assumptions (Details)	9 Months Ended
	Sep. 30, 2023 $ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Strike price (in dollars per share)	$ 2.63
Risk-free rate, minimum	3.60%
Risk-free rate, maximum	4.30%
Expected dividend yield	0%
Expected volatility, minimum	85.80%
Expected volatility, maximum	88.40%
Expected term (in years)	6 years
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Strike price (in dollars per share)	$ 2.50
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Strike price (in dollars per share)	$ 4.21

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Income Tax Disclosure [Abstract]
Income tax (benefit) expense	$ (318)	$ 50	$ (2,519)	$ 216
Effective income tax rate	6.40%	(0.90%)	21.40%	(1.30%)
Accrued interest and penalties	$ 2,100		$ 2,100

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2023	Dec. 31, 2022
Loss Contingencies [Line Items]
Costs accrued	$ 0	$ 250
Reversal of loss accrual	250
Purchase obligation	3,500
Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Costs accrued	475
Suits Filed In 2022
Loss Contingencies [Line Items]
Costs accrued	1,450
Minimum | Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Estimate of possible loss	475
Minimum | Suits Filed In 2022
Loss Contingencies [Line Items]
Estimate of possible loss	1,450
Maximum | Suit Against Goodwin and Simb
Loss Contingencies [Line Items]
Estimate of possible loss	2,500
Maximum | Suits Filed In 2022
Loss Contingencies [Line Items]
Estimate of possible loss	$ 2,400

RELATED PARTY TRANSACTIONS (Det

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Related Party Transaction [Line Items]
Accounts receivable	$ (12,648)		$ (12,648)		$ (10,602)
Co-venturer
Related Party Transaction [Line Items]
Purchases from related party	50	$ 85	501	$ 455
Accounts payable	$ 12		$ 12
Accounts receivable					$ (8)

GEOGRAPHIC AND SEGMENT INFORM_3

GEOGRAPHIC AND SEGMENT INFORMATION - Narrative (Details) - segment	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting [Abstract]
Number of reportable segments			2
Number of operating segments			2
International sales, percent of total revenue	27.80%	23.20%	26.60%	29.50%

GEOGRAPHIC AND SEGMENT INFORM_4

GEOGRAPHIC AND SEGMENT INFORMATION - Reportable Segment (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Sales	$ 11,976	$ 9,114	$ 37,687	$ 31,899
(Loss) income from operations	(4,637)	(5,782)	(11,483)	(17,629)	$ (23,600)
Interest income	248	73	478	93
Interest expense	(585)	(1)	(1,362)	(12)
Other income (loss), net	(19)	(35)	622	551
Income tax (benefit) expense	(318)	50	(2,519)	216
Operating Segments | Advanced Energy
Segment Reporting Information [Line Items]
Sales	9,836	7,080	31,248	26,258
(Loss) income from operations	70	(1,174)	(509)	(3,765)
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Operating Segments | OEM
Segment Reporting Information [Line Items]
Sales	2,140	2,034	6,439	5,641
(Loss) income from operations	591	356	1,795	1,142
Interest income	0	0	0	0
Interest expense	0	0	0	0
Other income (loss), net	0	0	0	0
Income tax (benefit) expense	0	0	0	0
Corporate & Other
Segment Reporting Information [Line Items]
Sales	0	0	0	0
(Loss) income from operations	(5,298)	(4,964)	(12,769)	(15,006)
Interest income	248	73	478	93
Interest expense	(585)	(1)	(1,362)	(12)
Other income (loss), net	(19)	(35)	622	551
Income tax (benefit) expense	$ (318)	$ 50	$ (2,519)	$ 216

GEOGRAPHIC AND SEGMENT INFORM_5

GEOGRAPHIC AND SEGMENT INFORMATION - Geographic (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2023	Sep. 30, 2022	Sep. 30, 2023	Sep. 30, 2022
Segment Reporting Information [Line Items]
Sales	$ 11,976	$ 9,114	$ 37,687	$ 31,899
Domestic
Segment Reporting Information [Line Items]
Sales	8,652	6,997	27,660	22,492
International
Segment Reporting Information [Line Items]
Sales	$ 3,324	$ 2,117	$ 10,027	$ 9,407